Menu Search
Equities

China Demeter Financial Investments Ltd

8120:HKG

China Demeter Financial Investments Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)0.045
  • Today's Change-0.405 / -90.00%
  • Shares traded440.01k
  • 1 Year change-96.72%
  • Beta-0.2772
Data delayed at least 15 minutes, as of Nov 14 2024 07:38 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in HKDIncome statement in HKDView more

Year on year China Demeter Financial Investments Ltd had net income fall 140.44% from a loss of 18.84m to a larger loss of 45.31m despite a 10.60% increase in revenues from 141.90m to 156.94m. An increase in the cost of goods sold as a percentage of sales from 32.49% to 33.50% was a component in the falling net income despite rising revenues.
Gross margin67.45%
Net profit margin-24.99%
Operating margin-21.94%
Return on assets-17.94%
Return on equity-39.01%
Return on investment-30.86%
More ▼

Cash flow in HKDView more

In 2023, cash reserves at China Demeter Financial Investments Ltd fell by 14.74m. However, the company earned 30.37m from its operations for a Cash Flow Margin of 19.35%. In addition the company used 10.58m on investing activities and also paid 34.53m in financing cash flows.
Cash flow per share0.0045
Price/Cash flow per share12.11
Book value per share0.0845
Tangible book value per share0.0818
More ▼

Balance sheet in HKDView more

China Demeter Financial Investments Ltd has a Debt to Total Capital ratio of 42.27%, a higher figure than the previous year's 19.89%.
Current ratio1.49
Quick ratio1.48
Total debt/total equity0.7307
Total debt/total capital0.4227
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.